Trial Outcomes & Findings for Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection (NCT NCT02202044)

NCT ID: NCT02202044

Last Updated: 2019-06-14

Results Overview

• Recruitment status: TERMINATED
• Study phase: NA
• Target enrollment: 13 participants
• Primary outcome timeframe: 5 years
• Results posted on: 2019-06-14

Participant Flow

The study was terminated before participants finished treatment and the PI is no longer in the institution to provide information for results reporting. No results information is available.

Participant milestones

Measure	Intravesical BCG and EMDA/MMC Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC Intravesical BCG and EMDA/MMC: Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
Overall Study STARTED	0
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 5 years

Population: The study was terminated before participants finished treatment and the PI is no longer in the institution to provide information for results reporting. No results information is available.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 5 years

Population: The study was terminated before participants finished treatment and the PI is no longer in the institution to provide information for results reporting. No results information is available.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 years

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 years

Outcome measures

Outcome data not reported

Adverse Events

Intravesical BCG and EMDA/MMC

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Tracey MacDermott

University of Colorado

Phone: 303-724-2757

Email: Tracey.MacDermott@ucdenver.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place